The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| DICERNA PHARMACEUTICALS INC | COM | 253031108 | 74,954 | 4,080,237 | SH | SOLE | 4,080,237 | 0 | 0 | ||
| MARINUS PHARMACEUTICALS INC | COM | 56854Q101 | 12,064 | 5,942,735 | SH | SOLE | 5,942,735 | 0 | 0 | ||
| REPLIMUNE GROUP INC | COM | 76029N106 | 28,305 | 2,838,968 | SH | SOLE | 2,838,968 | 0 | 0 | ||
| SOLID BIOSCIENCES INC | COM | 83422E105 | 9,252 | 3,871,164 | SH | SOLE | 3,871,164 | 0 | 0 | ||
| APTINYX INC | COM | 03836N103 | 12,006 | 5,558,425 | SH | SOLE | 5,558,425 | 0 | 0 | ||
| SPRINGWORKS THERAPEUTICS INC | COM | 85205L107 | 196,595 | 7,281,307 | SH | SOLE | 7,281,307 | 0 | 0 | ||
| DYNAVAX TECHNOLOGIES CORP. | COM | 268158201 | 30,819 | 8,730,707 | SH | SOLE | 8,730,707 | 0 | 0 | ||
| CONSTELLATION PHARMACEUTICALS INC. | COM | 210373106 | 69,257 | 2,203,529 | SH | SOLE | 2,203,529 | 0 | 0 | ||
| X4 PHARMACEUTICALS INC | COM | 98420X103 | 16,485 | 1,648,485 | SH | SOLE | 1,648,485 | 0 | 0 | ||
| SAVARA INC | COM | 805111101 | 22,976 | 5,128,593 | SH | SOLE | 5,128,593 | 0 | 0 | ||
| ARCUTIS BIOTHERAPEUTICS, INC. | COM | 03969K108 | 118,583 | 3,979,292 | SH | SOLE | 3,979,292 | 0 | 0 | ||